High expression of stromal FOXP3+ and stromal PDL1+ were the sole markers associated with all recurrences in DCIS patients treated with BCS (HR = 2.1, 95%CI = 1.1–3.7, p = 0.025 and HR = 4.4, 95%CI = 2.4–8.1, p < 0.0001, respectively); Fig. 4a, b. This evidence concerns the gene FOXP3 and ductal breast carcinoma in situ.